Clinical Trial
Results
Research Sponsor: MedImmune, LLC
Drug Studied: MEDI6012
National Clinical Trial #: NCT02601560
Protocol #: D5780C00002
Study Date: December 2015 to January 2017
Short Study Title: A study in participants with coronary artery
disease to see how MEDI6012 affects the
body, how MEDI6012 acts in the body, and
if MEDI6012 is safe to take
Thank you!
As a clinical study participant, you belong to a large community of
participants around the world. You help researchers answer important
health questions and discover new medical treatments.
Thank you for taking part in the clinical study for a drug called MEDI6012.
This drug is being developed to treat coronary artery disease, or CAD. You
and all of the other participants helped researchers learn how MEDI6012
affects the body, how MEDI6012 acts in the body, and if MEDI6012 is safe
to take.
MedImmune, LLC, the sponsor of this study, thanks you for your help
and thinks it is important for you to know the results of your study.
An independent non-profit organization called CISCRP prepared this
summary of the study results for you with the help of a medical writing
organization. We hope it helps you understand and feel proud of your
important role in medical research. If you have questions about the
results, please speak with the doctor or staff at your study site.